TXMD insider filings
TherapeuticsMD, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2025-12-29. Screen TXMD transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for TXMD between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — TherapeuticsMD, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-12-29 | 4 | Thompson Tommy G — Director | Purchase (P): 8,400 @ $1.67 | EDGAR |
| 2025-11-05 | 4 | Walker Marlan D — Chief Executive Officer | Grant/award (A): 67,492 (derivative) @ $0 | EDGAR |
| 2025-11-05 | 4 | Collins Cooper C. — Director | Grant/award (A): 8,500 (derivative) @ $0 | EDGAR |
| 2025-11-05 | 4 | Thompson Tommy G — Director | Grant/award (A): 8,500 (derivative) @ $0 | EDGAR |
| 2025-11-05 | 4 | Naughton Gail K — Director | Grant/award (A): 8,500 (derivative) @ $0 | EDGAR |
| 2025-04-15 | 4 | Walker Marlan D — Chief Executive Officer | Purchase (P): 490 @ $1.00 | EDGAR |
| 2025-04-15 | 4 | Thompson Tommy G — Director | Purchase (P): 325 @ $1.00 | EDGAR |
| 2025-04-10 | 4 | Walker Marlan D — Chief Executive Officer | Purchase (P): 1,136 @ $0.87 · Purchase (P): 1,167 @ $0.86 | EDGAR |
| 2025-02-20 | 4 | Walker Marlan D — Chief Executive Officer | Option exercise (M): 3,467 @ $0 · Option exercise (M): 2,311 @ $0 · Option exercise (M): 770 @ $0 · Option exercise (M): 1,733 @ $0 · Option exercise (M): 3,467 (derivative) @ $0 · Option exercise (M): 2,311 (derivative) @ $0 · +2 more | EDGAR |
| 2025-02-20 | 4 | Collins Cooper C. — Director | Option exercise (M): 8,500 @ $0 · Option exercise (M): 8,500 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Thompson Tommy G — Director | Option exercise (M): 8,500 @ $0 · Option exercise (M): 8,500 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Naughton Gail K — Director | Option exercise (M): 8,500 @ $0 · Option exercise (M): 8,500 (derivative) @ $0 | EDGAR |
| 2024-08-26 | 4 | Collins Cooper C. — Director | Purchase (P): 4,094 @ $1.73 | EDGAR |
| 2024-08-23 | 4 | Collins Cooper C. — Director | Purchase (P): 1,200 @ $1.70 | EDGAR |
| 2023-12-07 | 4 | Walker Marlan D — Chief Executive Officer | Option exercise (M): 70,000 @ $0 · Sale (S): 14,500 @ $2.31 · Sale (S): 4,550 @ $2.24 · Option exercise (M): 70,000 (derivative) @ $0 | EDGAR |
| 2023-11-17 | 4 | Rubric Capital Management LP — Director, 10% owner Rosen David Efraim — 10% owner | Grant/award (A): 877,192 @ $2.28 | EDGAR |
| 2023-08-21 | 4 | ZIEGLER JOSEPH — Principal Financial Officer | Grant/award (A): 7,500 @ $0 | EDGAR |
| 2023-07-19 | 4 | Collins Cooper C. — Director | Grant/award (A): 8,500 (derivative) @ $0 | EDGAR |
| 2023-07-19 | 4 | Thompson Tommy G — Director | Grant/award (A): 8,500 (derivative) @ $0 | EDGAR |
| 2023-07-19 | 4 | Naughton Gail K — Director | Grant/award (A): 8,500 (derivative) @ $0 | EDGAR |
| 2023-06-29 | 4 | Rubric Capital Management LP — Director, 10% owner Rosen David Efraim — Director, 10% owner | Grant/award (A): 312,525 @ $3.68 | EDGAR |
| 2023-05-04 | 4/A | Walker Marlan D — Chief Executive Officer | Option exercise (M): 1,010 @ $0 · Option exercise (M): 1,734 @ $0 · Sale (S): 692 @ $3.64 · Option exercise (M): 1,010 (derivative) @ $0 · Option exercise (M): 1,734 (derivative) @ $0 | EDGAR |
| 2023-04-14 | 4 | Walker Marlan D — Chief Executive Officer | Option exercise (M): 3,030 @ $0 · Option exercise (M): 1,010 @ $0 · Option exercise (M): 1,734 @ $0 · Option exercise (M): 1,734 @ $0 · Sale (S): 1,170 @ $3.65 · Option exercise (M): 3,030 (derivative) @ $0 · +3 more | EDGAR |
| 2023-04-14 | 4 | Donegan Michael C — Prin. Fin. and Acctg. Officer | Option exercise (M): 50,000 @ $0 · Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2023-02-23 | 4 | Walker Marlan D — Chief Executive Officer | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2023-02-23 | 4 | Donegan Michael C — Prin. Fin. and Acctg. Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2023-02-22 | 4/A | Rubric Capital Management LP — Director, 10% owner Rosen David Efraim — Director, 10% owner | Disposition to issuer (D): 29,000 @ $1,333 | EDGAR |
| 2023-01-30 | 4 | Donegan Michael C — Prin. Fin. and Acctg. Officer | Option exercise (M): 2,400 @ $0 · Option exercise (M): 2,400 @ $0 · Option exercise (M): 1,140 @ $0 · Sale (S): 1,648 @ $5.08 · Sale (S): 49 @ $5.09 · Option exercise (M): 2,400 (derivative) @ $0 · +2 more | EDGAR |
| 2023-01-25 | 4 | Donegan Michael C — Prin. Fin. and Acctg. Officer | Option exercise (M): 380 @ $0 · Option exercise (M): 1,066 @ $0 · Option exercise (M): 519 @ $0 · Option exercise (M): 2,400 @ $0 · Sale (S): 1,302 @ $5.34 · Sale (S): 7 @ $5.31 · +4 more | EDGAR |
| 2023-01-03 | 4 | Rubric Capital Management LP — 10% owner Rosen David Efraim — 10% owner | Sale (S): 29,000 @ $1,333 | EDGAR |
| 2022-12-12 | 4 | Rubric Capital Management LP — 10% owner Rosen David Efraim — 10% owner | Purchase (P): 14,825 @ $6.09 | EDGAR |
| 2022-12-09 | 4 | Walker Marlan D — General Counsel | Option exercise (M): 1,010 @ $0 · Option exercise (M): 1,156 @ $0 · Option exercise (M): 388 @ $0 · Sale (S): 1,048 @ $4.95 · Option exercise (M): 1,010 (derivative) @ $0 · Option exercise (M): 1,156 (derivative) @ $0 · +1 more | EDGAR |
| 2022-12-09 | 4 | Rubric Capital Management LP — 10% owner Rosen David Efraim — 10% owner | Purchase (P): 20,113 @ $5.66 · Purchase (P): 300 @ $5.83 | EDGAR |
| 2022-12-09 | 4 | Donegan Michael C — Interim CFO/CAO/VP of Finance | Option exercise (M): 2,300 @ $0 · Option exercise (M): 380 @ $0 · Option exercise (M): 534 @ $0 · Option exercise (M): 262 @ $0 · Sale (S): 910 @ $4.78 · Option exercise (M): 2,300 (derivative) @ $0 · +3 more | EDGAR |
| 2022-12-09 | 4 | Bernick Brian — Co-Chief Executive Officer | Option exercise (M): 3,167 @ $0 · Sale (S): 935 @ $4.92 · Sale (S): 320 @ $6.31 · Option exercise (M): 3,167 (derivative) @ $0 | EDGAR |
| 2022-12-09 | 4 | Glickman Mark A — Co-Chief Executive Officer | Option exercise (M): 1,734 @ $0 · Sale (S): 440 @ $4.92 · Option exercise (M): 1,734 (derivative) @ $0 | EDGAR |
| 2022-12-08 | 4 | Naughton Gail K — Director | Sale (S): 3,922 @ $5.26 | EDGAR |
| 2022-10-31 | 4 | Rubric Capital Management LP — 10% owner Rosen David Efraim — 10% owner | Purchase (P): 7,000 @ $1,000 | EDGAR |
| 2022-10-03 | 4 | Rubric Capital Management LP — 10% owner Rosen David Efraim — 10% owner | Purchase (P): 7,000 @ $1,000 | EDGAR |
| 2022-10-03 | 4 | Ling Karen — Director | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2022-10-03 | 4 | Russell Angus C. — Director | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2022-10-03 | 4 | MUSING JULES A. — Director | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2022-10-03 | 4 | Collins Cooper C. — Director | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2022-10-03 | 4 | Thompson Tommy G — Director | Grant/award (A): 34,175 (derivative) @ $0 | EDGAR |
| 2022-10-03 | 4 | Naughton Gail K — Director | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2022-10-03 | 4 | BISARO PAUL — Director | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2022-08-22 | 4 | Collins Cooper C. — Director | Option exercise (M): 1,984 · Option exercise (M): 1,984 (derivative) @ $0 | EDGAR |
| 2022-08-22 | 4 | Thompson Tommy G — Director | Option exercise (M): 2,976 · Option exercise (M): 2,976 (derivative) @ $0 | EDGAR |
| 2022-08-22 | 4 | Naughton Gail K — Director | Option exercise (M): 1,984 · Option exercise (M): 1,984 (derivative) @ $0 | EDGAR |
| 2022-08-22 | 4 | BISARO PAUL — Director | Option exercise (M): 1,984 · Option exercise (M): 1,984 (derivative) @ $0 | EDGAR |
Recent 8-K events — TherapeuticsMD, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-13 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-11 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-30 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-21 | 8-K | 4.01 — Changes in Registrant's Certifying Accountant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-16 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2025-11-13 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-05-13 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-04-09 | 8-K | 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=TXMD returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs